Luca Issi

Yanan Zhu

Brian Cheng

David Lebowitz

Jay Olson

Maurice Raycroft

Rick Bienkowski

William Pickering

Alec Stranahan

Andy Chen

Huidong Wang

Joseph Thome

Konstantinos Biliouris

Mani Foroohar

Mitchell Kapoor

Myles Minter

Salveen Richter

Silvan Tuerkcan

Troy Langford

Brandon Frith

Cheng Li

Dae Gon Ha

Farzin Haque

Gena Wang

Hang Hu

Hannah Tran

Jonathan Miller

Joon Lee

Kostas Biliouris

Liisa Bayko

Lili Nsongo

Lut Ming Cheng

Mark Aleynick

Matthew Guggenbiller

Matthew Harrison

Mehdi Goudarzi

Ry Forseth

Terence Flynn

Whitney Ijem

William Sanger

Yuriy Slutskyy

- Intellia Therapeutics, Inc. announced positive longer-term Phase 1 data for **nexiguran ziclumeran (nex-z)** in patients with hereditary transthyretin (ATTR) amyloidosis with polyneuropathy (ATTRv-PN).  **[1652130_0001193125-25-217484_d870108dex991.htm:0]** **[1652130_0001193125-25-217484_d870108d8k.htm:2]** 
- A single dose of nex-z led to mean serum TTR reductions of **92% at 24 months** (n=33) and **90% at 36 months** (n=12) from baseline.  **[1652130_0001193125-25-217484_d870108dex991.htm:0]** **[1652130_0001193125-25-217484_d870108d8k.htm:2]** 
- Favorable trends in clinical measures were observed, with **72% of patients** (13 out of 18) showing clinically meaningful improvements in mNIS+7 at 24 months, and **89% of patients** demonstrating improvement or stability in PND scores through 24 months.  **[1652130_0001193125-25-217484_d870108dex991.htm:1]** **[1652130_0001193125-25-217484_d870108d8k.htm:2]** 
- The company expects to complete enrollment in the Phase 3 MAGNITUDE-2 trial in the **first half of 2026** and anticipates submitting a Biologics License Application (BLA) for ATTRv-PN by **2028**.  **[1652130_0001193125-25-217484_d870108dex991.htm:0]** **[1652130_0001193125-25-217484_d870108dex991.htm:1]** **[1652130_0001193125-25-217484_d870108d8k.htm:2]** **[1652130_0001193125-25-217484_d870108d8k.htm:3]** **[1652130_0001193125-25-217484_d870108dex991.htm:3]**

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran

Intellia Therapeutics (NTLA)